[go: up one dir, main page]

DK2010496T3 - 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer - Google Patents

4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer

Info

Publication number
DK2010496T3
DK2010496T3 DK07732381.4T DK07732381T DK2010496T3 DK 2010496 T3 DK2010496 T3 DK 2010496T3 DK 07732381 T DK07732381 T DK 07732381T DK 2010496 T3 DK2010496 T3 DK 2010496T3
Authority
DK
Denmark
Prior art keywords
anilinoquinoline
csf
carboxylic acid
acid amides
kinase inhibitors
Prior art date
Application number
DK07732381.4T
Other languages
English (en)
Inventor
Valle David Del
Donald Cook
Leslie Dakin
Thomas Gero
David Scott
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2010496T3 publication Critical patent/DK2010496T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
DK07732381.4T 2006-04-14 2007-04-12 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer DK2010496T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74485706P 2006-04-14 2006-04-14
US86509006P 2006-11-09 2006-11-09
PCT/GB2007/001338 WO2007119046A1 (en) 2006-04-14 2007-04-12 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2010496T3 true DK2010496T3 (da) 2010-11-08

Family

ID=38268859

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07732381.4T DK2010496T3 (da) 2006-04-14 2007-04-12 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer

Country Status (27)

Country Link
US (1) US20090054411A1 (da)
EP (1) EP2010496B1 (da)
JP (1) JP2009533405A (da)
KR (1) KR20080112380A (da)
CN (1) CN101466682A (da)
AR (1) AR060508A1 (da)
AT (1) ATE478849T1 (da)
AU (1) AU2007238372A1 (da)
BR (1) BRPI0710191A2 (da)
CA (1) CA2649146A1 (da)
CY (1) CY1111203T1 (da)
DE (1) DE602007008710D1 (da)
DK (1) DK2010496T3 (da)
EC (1) ECSP088828A (da)
HR (1) HRP20100580T1 (da)
IL (1) IL194424A0 (da)
MX (1) MX2008013212A (da)
NO (1) NO20084202L (da)
PL (1) PL2010496T3 (da)
PT (1) PT2010496E (da)
RS (1) RS51483B (da)
RU (1) RU2008144806A (da)
SI (1) SI2010496T1 (da)
TW (1) TW200808732A (da)
UY (1) UY30282A1 (da)
WO (1) WO2007119046A1 (da)
ZA (1) ZA200808599B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
TW200948803A (en) * 2008-05-07 2009-12-01 Astrazeneca Ab Chemical compounds
AR076766A1 (es) * 2009-05-14 2011-07-06 Japan Tobacco Inc Compuestos de azetidina, composiciones farmaceuticas y su uso en el tratamiento de enfermedades autoinmunes.
BR112013002182B8 (pt) 2010-07-30 2023-02-28 Oncotherapy Science Inc Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
US20130225524A1 (en) * 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
WO2012151541A1 (en) * 2011-05-05 2012-11-08 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
CA2834696C (en) * 2011-05-05 2019-07-23 Novartis Ag Csf-1r inhibitors for treatment of brain tumors
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
MX366983B (es) 2012-01-19 2019-08-01 Oncotherapy Science Inc Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3294417B1 (en) 2015-05-08 2021-10-13 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109700794B (zh) * 2017-03-01 2021-01-08 浙江大学 腙结构类型雄激素受体拮抗剂及其应用
WO2022063134A1 (zh) * 2020-09-23 2022-03-31 中国科学院上海药物研究所 Csf1r激酶抑制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP4548642B2 (ja) * 1998-09-29 2010-09-22 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
HU230728B1 (hu) * 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
US7598258B2 (en) * 2002-05-01 2009-10-06 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
MXPA06002846A (es) * 2003-09-15 2006-06-14 Wyeth Corp Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa.
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1

Also Published As

Publication number Publication date
AU2007238372A1 (en) 2007-10-25
CN101466682A (zh) 2009-06-24
ECSP088828A (es) 2008-11-27
NO20084202L (no) 2008-10-08
US20090054411A1 (en) 2009-02-26
BRPI0710191A2 (pt) 2012-06-05
AR060508A1 (es) 2008-06-25
HK1126199A1 (en) 2009-08-28
PT2010496E (pt) 2010-10-13
EP2010496A1 (en) 2009-01-07
ZA200808599B (en) 2009-11-25
IL194424A0 (en) 2009-08-03
RU2008144806A (ru) 2010-05-20
UY30282A1 (es) 2007-11-30
MX2008013212A (es) 2008-10-22
JP2009533405A (ja) 2009-09-17
SI2010496T1 (sl) 2010-11-30
KR20080112380A (ko) 2008-12-24
HRP20100580T1 (hr) 2010-11-30
TW200808732A (en) 2008-02-16
WO2007119046A1 (en) 2007-10-25
PL2010496T3 (pl) 2011-01-31
CA2649146A1 (en) 2007-10-25
ATE478849T1 (de) 2010-09-15
CY1111203T1 (el) 2015-06-11
EP2010496B1 (en) 2010-08-25
RS51483B (sr) 2011-04-30
DE602007008710D1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
DK2010496T3 (da) 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
DK2178840T3 (da) Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK2125748T3 (da) Acylaminopyrazol som FGFR inhibitorer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2300013T4 (da) Phosphorderivater som kinasehæmmere
LT3354650T (lt) Junginiai, naudingi kaip atr kinazės inhibitoriai
CR10693A (es) Enantiomerically pure phosphoindoles as hiv inhibitors
DK2402317T3 (da) DGAT-inhibitor
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1981892T3 (da) Thienopyridinderivater som mek-inhibitorer
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
BRPI0922880A2 (pt) compostos inibidores de quinase